Perifosine enhances the potential antitumor effect of 5-fluorourasil and oxaliplatin in colon cancer cells harboring the PIK3CA mutation
Authors:
- 1 May 2021
- journal article
- research article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 898, 173957
Abstract
No abstract availableKeywords
Funding Information
- Japan Society for the Promotion of Science
This publication has 21 references indexed in Scilit:
- Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E MutationCancer Discovery, 2016
- Prognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysisAnnals of Oncology, 2016
- MicroRNA-204 modulates colorectal cancer cell sensitivity in response to 5-fluorouracil-based treatment by targeting high mobility group protein A2Biology Open, 2016
- Global cancer statistics, 2012CA: A Cancer Journal for Clinicians, 2015
- Nitrogen-containing bisphosphonates inhibit RANKL- and M-CSF-induced osteoclast formation through the inhibition of ERK1/2 and Akt activationJournal of Biomedical Science, 2014
- Randomized Placebo-Controlled Phase II Trial of Perifosine Plus Capecitabine As Second- or Third-Line Therapy in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2011
- KRAS Gene Mutation in Colorectal Cancer Is Correlated With Increased Proliferation and Spontaneous ApoptosisAmerican Journal of Clinical Pathology, 2011
- Reduction of lung metastasis, cell invasion, and adhesion in mouse melanoma by statin-induced blockade of the Rho/Rho-associated coiled-coil-containing protein kinase pathwayJournal of Experimental & Clinical Cancer Research, 2010
- Mutations of the BRAF gene in human cancerNature, 2002
- Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitorsAdvances in Enzyme Regulation, 1984